High-Intensity Statins for Secondary Prevention

Comment

. 2017 Jan 1;2(1):55.

doi: 10.1001/jamacardio.2016.4479.

Comment

Robert O Bonow et al. JAMA Cardiol. 2017.

. 2017 Jan 1;2(1):55.

doi: 10.1001/jamacardio.2016.4479.

No abstract available

Comment on

Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Rodriguez F, et al. JAMA Cardiol. 2017 Jan 1;2(1):47-54. doi: 10.1001/jamacardio.2016.4052. JAMA Cardiol. 2017. PMID: 27829091

[Treatment of dyslipidemias with statins in primary and seconary prevention].
Janin A. Janin A. Rev Med Suisse. 2015 Apr 1;11(468):787-8. Rev Med Suisse. 2015. PMID: 26021142 French. No abstract available.
Suboptimal use of statins for secondary cardiovascular prevention: a "planetary" issue.
Bellia A, Della-Morte D, Lauro D. Bellia A, et al. Intern Emerg Med. 2017 Dec;12(8):1091-1092. doi: 10.1007/s11739-017-1749-y. Epub 2017 Sep 14. Intern Emerg Med. 2017. PMID: 28913788 No abstract available.
Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma.
Aronow WS. Aronow WS. J Am Geriatr Soc. 2009 Oct;57(10):1942-3; author reply 1943-4. doi: 10.1111/j.1532-5415.2009.02456.x. J Am Geriatr Soc. 2009. PMID: 19807799 No abstract available.
Statins: have we found the Holy Grail?
Jeger R, Dieterle T. Jeger R, et al. Swiss Med Wkly. 2012 Feb 3;142:w13515. doi: 10.4414/smw.2012.13515. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22315166 Review.
Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
Lardizabal JA, Deedwania P. Lardizabal JA, et al. Cardiol Clin. 2011 Feb;29(1):87-103. doi: 10.1016/j.ccl.2010.10.002. Cardiol Clin. 2011. PMID: 21257102 Review.